These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 17156009)

  • 1. alpha-Synuclein, oxidative stress and apoptosis from the perspective of a yeast model of Parkinson's disease.
    Witt SN; Flower TR
    FEMS Yeast Res; 2006 Dec; 6(8):1107-16. PubMed ID: 17156009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heat shock prevents alpha-synuclein-induced apoptosis in a yeast model of Parkinson's disease.
    Flower TR; Chesnokova LS; Froelich CA; Dixon C; Witt SN
    J Mol Biol; 2005 Sep; 351(5):1081-100. PubMed ID: 16051265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Yeast unfolds the road map toward alpha-synuclein-induced cell death.
    Franssens V; Boelen E; Anandhakumar J; Vanhelmont T; Büttner S; Winderickx J
    Cell Death Differ; 2010 May; 17(5):746-53. PubMed ID: 20019751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rescuing defective vesicular trafficking protects against alpha-synuclein toxicity in cellular and animal models of Parkinson's disease.
    Lashuel HA; Hirling H
    ACS Chem Biol; 2006 Aug; 1(7):420-4. PubMed ID: 17168518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions.
    Chu Y; Dodiya H; Aebischer P; Olanow CW; Kordower JH
    Neurobiol Dis; 2009 Sep; 35(3):385-98. PubMed ID: 19505575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiapoptotic property of human alpha-synuclein in neuronal cell lines is associated with the inhibition of caspase-3 but not caspase-9 activity.
    Li W; Lee MK
    J Neurochem; 2005 Jun; 93(6):1542-50. PubMed ID: 15935070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rescue of alpha-synuclein cytotoxicity by insulin-like growth factors.
    Kao SY
    Biochem Biophys Res Commun; 2009 Jul; 385(3):434-8. PubMed ID: 19470380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Saccharomyces cerevisiae strain unable to store neutral lipids is tolerant to oxidative stress induced by α-synuclein.
    Sere YY; Regnacq M; Colas J; Berges T
    Free Radic Biol Med; 2010 Dec; 49(11):1755-64. PubMed ID: 20850523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aggregation-defective alpha-synuclein mutants inhibit the fibrillation of Parkinson's disease-linked alpha-synuclein variants.
    Koo HJ; Choi MY; Im H
    Biochem Biophys Res Commun; 2009 Aug; 386(1):165-9. PubMed ID: 19501571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation of a alpha-synuclein-based rat model of Parkinson's disease.
    Recchia A; Rota D; Debetto P; Peroni D; Guidolin D; Negro A; Skaper SD; Giusti P
    Neurobiol Dis; 2008 Apr; 30(1):8-18. PubMed ID: 18313315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toxic effects of dopamine metabolism in Parkinson's disease.
    Hattoria N; Wanga M; Taka H; Fujimura T; Yoritaka A; Kubo S; Mochizuki H
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S35-8. PubMed ID: 19131041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alpha-synuclein overexpression and aggregation exacerbates impairment of mitochondrial functions by augmenting oxidative stress in human neuroblastoma cells.
    Parihar MS; Parihar A; Fujita M; Hashimoto M; Ghafourifar P
    Int J Biochem Cell Biol; 2009 Oct; 41(10):2015-24. PubMed ID: 19460457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pragmatic approach to biochemical systems theory applied to an alpha-synuclein-based model of Parkinson's disease.
    Sass MB; Lorenz AN; Green RL; Coleman RA
    J Neurosci Methods; 2009 Apr; 178(2):366-77. PubMed ID: 19136028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synuclein, dopamine and oxidative stress: co-conspirators in Parkinson's disease?
    Maguire-Zeiss KA; Short DW; Federoff HJ
    Brain Res Mol Brain Res; 2005 Mar; 134(1):18-23. PubMed ID: 15790526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dissecting the potential molecular mechanisms underlying alpha-synuclein cell-to-cell transfer in Parkinson's disease.
    Angot E; Brundin P
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S143-7. PubMed ID: 20082977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disruption of dopamine homeostasis underlies selective neurodegeneration mediated by alpha-synuclein.
    Park SS; Schulz EM; Lee D
    Eur J Neurosci; 2007 Dec; 26(11):3104-12. PubMed ID: 18005066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Controlling the mass action of alpha-synuclein in Parkinson's disease.
    Kim C; Lee SJ
    J Neurochem; 2008 Oct; 107(2):303-16. PubMed ID: 18691382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphorylation does not prompt, nor prevent, the formation of alpha-synuclein toxic species in a rat model of Parkinson's disease.
    Azeredo da Silveira S; Schneider BL; Cifuentes-Diaz C; Sage D; Abbas-Terki T; Iwatsubo T; Unser M; Aebischer P
    Hum Mol Genet; 2009 Mar; 18(5):872-87. PubMed ID: 19074459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alpha-synuclein and Parkinson's disease: a proteomic view.
    Fasano M; Lopiano L
    Expert Rev Proteomics; 2008 Apr; 5(2):239-48. PubMed ID: 18466054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopamine and the dopamine oxidation product 5,6-dihydroxylindole promote distinct on-pathway and off-pathway aggregation of alpha-synuclein in a pH-dependent manner.
    Pham CL; Leong SL; Ali FE; Kenche VB; Hill AF; Gras SL; Barnham KJ; Cappai R
    J Mol Biol; 2009 Apr; 387(3):771-85. PubMed ID: 19361420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.